HARVARD BIOSCIENCE INC Investment Update

Hey there! Let's unpack some fresh news from Harvard Bioscience that just hit. Think of this as me explaining it to you over a coffee, without all the confusing finance talk.

What Happened & Why It Matters

On March 17, 2026, Harvard Bioscience publicly filed its latest corporate presentation with the SEC, the government body overseeing public companies. This isn't just a routine update; it's a comprehensive look at a major transformation underway at the company. By filing it, Harvard Bioscience ensures all investors receive the same crucial information simultaneously, adhering to 'Regulation FD' (Fair Disclosure). The presentation offers a direct window into the company's new strategic direction, recent financial performance, and future plans, especially significant given its new leadership.

Key Highlights from the Presentation

Here’s what you need to know from this pivotal presentation:

• Major Strategic Pivot: Harvard Bioscience is transforming into a 'pure-play Translational Science Tools company.' This means they are sharpening their focus on developing tools that accelerate drug discovery and development through 'human-relevant' methods. This shift is crucial because new regulations and scientific advancements increasingly demand better predictive models, moving away from traditional animal testing. Their goal is to help scientists develop drugs faster and more effectively, particularly in areas like organoid platforms and advanced electrophysiology.
• New Leadership & Governance: A fresh vision often brings new leadership. The company appointed John Duke CEO in July 2025 and Mark Frost permanent CFO in March 2026. Harvard Bioscience also expanded its Board of Directors, signaling a strong commitment to this new strategic direction.
• Financial Strengthening & Operational Efficiency:
  • Debt Refinancing: Harvard Bioscience successfully refinanced its debt, extending maturity to 2029. This move is expected to save approximately $3 million annually in cash interest payments, providing more financial flexibility.
  • Operational Streamlining: To boost efficiency and profitability, Harvard Bioscience will close its manufacturing plant in Holliston, MA. This consolidation projects an improvement in adjusted EBITDA by $3-4 million annually by 2027-2028.
• Solid Financial Performance (FY2025): The presentation highlights their recent financial health:
  • Revenue: $87 million
  • Recurring Revenue: A strong 54% of total revenue, indicating stable, predictable income from sources like software and consumables.
  • Adjusted EBITDA: $8.1 million
• Positive 2026 Outlook: Looking ahead, the company projects continued growth:
  • Revenue Growth: 2-4% for the full year 2026.
  • Adjusted EBITDA Growth: 6-10% for the full year 2026.
• Product Pipeline & Innovation: The presentation details key product initiatives such as MeshMEA, SoHo, and Incub8. These are central to Harvard Bioscience's strategy of integrating in vivo telemetry with in vitro organoid platforms and scaling high-margin innovation.

Who's Affected?

• The Company: Undergoing significant transformation with new leadership, a focused strategic direction, and operational changes.
• Investors/Traders: This presentation is a vital resource to understand the company's new strategy, financial health, and future prospects. The detailed financial guidance, debt refinancing, and plant closure are key for investment decisions.
• Customers: Can expect new, improved products and services, particularly in cutting-edge areas like organoid platforms and advanced electrophysiology, aligning with the shift toward 'human-relevant' drug development.
• Employees: New leadership and strategic shifts will impact employees, with the Holliston plant closure being a direct example of efficiency efforts.
• Competitors: Will closely watch Harvard Bioscience's push into New Approach Methodologies (NAMs) and organoid research, rapidly growing segments.

What's Next & Your Bottom Line

Interested investors should immediately find and review the actual corporate presentation (Exhibit 99.1). This document offers deeper insights into Harvard Bioscience's vision, strategic pillars, and product roadmap. The company will likely continue executing its new strategic direction, and the market will watch to see if these changes lead to projected growth and improved profitability.

For your money, here's the bottom line: The act of filing this presentation is generally neutral for the stock price. Any impact, positive or negative, will stem from the information within the presentation itself. While the strategic pivot and financial improvements are promising, remember that significant transformations carry execution risks, market adoption challenges, and competitive pressures. Always conduct your own research and consider how this fits your overall investment strategy. This filing simply points to a new, official source of information outlining a significant new chapter for Harvard Bioscience.